Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Could MariTide one day steal market share from the likes of Wegovy and Zepbound, given its somewhat mediocre mid-stage data? The answer to that question is unambiguously yes, for three reasons.

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

Salim Syed has given his Hold rating due to a combination of factors surrounding Amgen’s recent data on MariTide, a potential treatment for obesity. The efficacy results from the 52-week Phase 2 ...

If MariTide achieves 22-23% weight loss in the phase 3 trial and CagriSema and retatrutide are in the 24-27% range which I estimated based on the available phase 2 data, I do not believe that the ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy and Mounjaro, but with fewer doses.

"MariTide and all of the GLP-1 medications have similar side effect profiles: nausea, vomiting, abdominal pain, constipation and less commonly pancreatic irritation," says Dr. Nadler.

--Amgen today announced full results from Part 1 of the Phase 2 study of MariTide, a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In addition to ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly injection treatment.

By Katherine Hamilton Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea. The drug ...